Neuronetics (NASDAQ: STIM) is one of 12,923 publicly-traded companies in the “” industry, but how does it contrast to its peers? We will compare Neuronetics to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, earnings, dividends and profitability.

Valuation & Earnings

This table compares Neuronetics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Neuronetics $52.78 million -$24.10 million -5.98
Neuronetics Competitors $7.26 billion $564.25 million 12.37

Neuronetics’ peers have higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

71.3% of Neuronetics shares are held by institutional investors. Comparatively, 56.1% of shares of all “” companies are held by institutional investors. 13.4% of shares of all “” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Neuronetics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuronetics N/A N/A N/A
Neuronetics Competitors -173.46% 8.30% 2.21%

Analyst Ratings

This is a breakdown of current recommendations for Neuronetics and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuronetics 0 0 5 0 3.00
Neuronetics Competitors 58919 224112 291429 11962 2.44

Neuronetics currently has a consensus target price of $32.25, suggesting a potential upside of 100.44%. As a group, “” companies have a potential upside of 24.27%. Given Neuronetics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Neuronetics is more favorable than its peers.

Summary

Neuronetics peers beat Neuronetics on 7 of the 12 factors compared.

Neuronetics Company Profile

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.